X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PIRAMAL ENTERPRISES - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PIRAMAL ENTERPRISES DR. REDDYS LAB/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 32.0 10.9 292.6% View Chart
P/BV x 3.4 1.9 182.1% View Chart
Dividend Yield % 0.8 0.9 88.7%  

Financials

 DR. REDDYS LAB   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
PIRAMAL ENTERPRISES
Mar-18
DR. REDDYS LAB/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,7883,083 90.4%   
Low Rs1,9021,902 100.0%   
Sales per share (Unadj.) Rs860.8589.7 146.0%  
Earnings per share (Unadj.) Rs57.1284.0 20.1%  
Cash flow per share (Unadj.) Rs122.0310.5 39.3%  
Dividends per share (Unadj.) Rs20.0025.00 80.0%  
Dividend yield (eoy) %0.91.0 85.0%  
Book value per share (Unadj.) Rs757.71,467.0 51.7%  
Shares outstanding (eoy) m165.91180.27 92.0%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.74.2 64.5%   
Avg P/E ratio x41.18.8 468.2%  
P/CF ratio (eoy) x19.28.0 239.4%  
Price / Book Value ratio x3.11.7 182.1%  
Dividend payout %35.08.8 398.2%   
Avg Mkt Cap Rs m389,034449,332 86.6%   
No. of employees `00023.56.8 343.8%   
Total wages/salary Rs m32,14919,881 161.7%   
Avg. sales/employee Rs Th6,070.815,535.6 39.1%   
Avg. wages/employee Rs Th1,366.62,905.4 47.0%   
Avg. net profit/employee Rs Th402.57,482.5 5.4%   
INCOME DATA
Net Sales Rs m142,810106,310 134.3%  
Other income Rs m1,5522,595 59.8%   
Total revenues Rs m144,362108,906 132.6%   
Gross profit Rs m23,51251,599 45.6%  
Depreciation Rs m10,7724,773 225.7%   
Interest Rs m78829,783 2.6%   
Profit before tax Rs m13,50419,638 68.8%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380-28,764 -15.2%   
Profit after tax Rs m9,46851,203 18.5%  
Gross profit margin %16.548.5 33.9%  
Effective tax rate %32.4-146.5 -22.1%   
Net profit margin %6.648.2 13.8%  
BALANCE SHEET DATA
Current assets Rs m104,984118,154 88.9%   
Current liabilities Rs m68,938462,260 14.9%   
Net working cap to sales %25.2-323.7 -7.8%  
Current ratio x1.50.3 595.8%  
Inventory Days Days7427 279.8%  
Debtors Days Days10447 222.6%  
Net fixed assets Rs m104,385113,727 91.8%   
Share capital Rs m830361 230.2%   
"Free" reserves Rs m124,886264,093 47.3%   
Net worth Rs m125,716264,454 47.5%   
Long term debt Rs m25,089242,206 10.4%   
Total assets Rs m225,443726,834 31.0%  
Interest coverage x18.11.7 1,093.0%   
Debt to equity ratio x0.20.9 21.8%  
Sales to assets ratio x0.60.1 433.1%   
Return on assets %4.511.1 40.8%  
Return on equity %7.519.4 38.9%  
Return on capital %9.710.3 94.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62315,110 480.6%   
Fx outflow Rs m18,9164,298 440.2%   
Net fx Rs m53,70710,813 496.7%   
CASH FLOW
From Operations Rs m18,030-159,666 -11.3%  
From Investments Rs m-14,883-17,677 84.2%  
From Financial Activity Rs m-4,440186,503 -2.4%  
Net Cashflow Rs m-1,2369,364 -13.2%  

Share Holding

Indian Promoters % 25.5 52.9 48.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.0 135.0%  
FIIs % 35.3 26.6 132.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 16.5 92.7%  
Shareholders   75,885 93,274 81.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - LUPIN LTD COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS